UBS Group
MCRB icon

UBS Group’s Seres Therapeutics MCRB Stock Holding History

UBS Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.82K Sell
484
-6,546
-93% -$49.8K ﹤0.01% 9142
2026
Q1 		$62.4K Buy
7,030
+2,804
+66% +$32.8K ﹤0.01% 7247
2025
Q4 		$62.9K Sell
4,226
-8,456
-67% -$147K ﹤0.01% 7117
2025
Q3 		$244K Buy
12,682
+5,150
+68% +$82.2K ﹤0.01% 6559
2025
Q2 		$83.7K Sell
7,532
-65,276
-90% -$574K ﹤0.01% 7381
2025
Q1 		$1.02M Buy
72,808
+55,692
+325% +$872K ﹤0.01% 5275
2024
Q4 		$284K Buy
17,116
+15,396
+895% +$250K ﹤0.01% 6230
2024
Q3 		$32.5K Sell
1,720
-8,316
-83% -$169K ﹤0.01% 7088
2024
Q2 		$145K Buy
10,036
+4,738
+89% +$79K ﹤0.01% 5893
2024
Q1 		$82K Buy
5,298
+4,895
+1,215% +$106K ﹤0.01% 6305
2023
Q4 		$11.3K Sell
403
-7,904
-95% -$208K ﹤0.01% 7398
2023
Q3 		$395K Buy
8,307
+4,645
+127% +$354K ﹤0.01% 4843
2023
Q2 		$351K Sell
3,662
-1,843
-33% -$201K ﹤0.01% 5105
2023
Q1 		$624K Sell
5,505
-5,557
-50% -$601K ﹤0.01% 4526
2022
Q4 		$1.24M Buy
11,062
+9,273
+518% +$1.24M ﹤0.01% 3867
2022
Q3 		$229K Buy
1,789
+1,608
+888% +$165K ﹤0.01% 4970
2022
Q2 		$12K Sell
181
-4,509
-96% -$388K ﹤0.01% 7666
2022
Q1 		$668K Buy
4,690
+4,457
+1,913% +$686K ﹤0.01% 4467
2021
Q4 		$39K Sell
233
-19,560
-99% -$3.11M ﹤0.01% 7149
2021
Q3 		$2.75M Buy
19,793
+19,394
+4,861% +$3.79M ﹤0.01% 3284
2021
Q2 		$190K Sell
399
-11
-3% -$4.64K ﹤0.01% 5389
2021
Q1 		$168K Buy
410
+320
+356% +$147K ﹤0.01% 5600
2020
Q4 		$44K Sell
90
-360
-80% -$211K ﹤0.01% 6300
2020
Q3 		$255K Buy
450
+415
+1,186% +$138K ﹤0.01% 4645
2020
Q2 		$3K Sell
35
-592
-94% -$51.9K ﹤0.01% 7546
2020
Q1 		$45K Sell
627
-1,391
-69% -$93.3K ﹤0.01% 5912
2019
Q4 		$139K Buy
2,018
+913
+83% +$67.7K ﹤0.01% 5828
2019
Q3 		$88K Buy
1,105
+1,040
+1,600% +$68.7K ﹤0.01% 5841
2019
Q2 		$4K Sell
65
-35
-35% -$3.32K ﹤0.01% 7457
2019
Q1 		$14K Sell
100
-59
-37% -$7.19K ﹤0.01% 6588
2018
Q4 		$15K Buy
159
+119
+298% +$16.7K ﹤0.01% 6993
2018
Q3 		$6K Sell
40
-100
-71% -$16.2K ﹤0.01% 7408
2018
Q2 		$24K Buy
140
+35
+33% +$5.72K ﹤0.01% 6571
2018
Q1 		$15K Sell
105
-25
-19% -$4.79K ﹤0.01% 6616
2017
Q4 		$26K Hold
130
– – ﹤0.01% 6354
2017
Q3 		$42K Sell
130
-124
-49% -$33.9K ﹤0.01% 5912
2017
Q2 		$57K Sell
254
-13
-5% -$2.67K ﹤0.01% 5558
2017
Q1 		$60K Buy
267
+112
+72% +$22.7K ﹤0.01% 5387
2016
Q4 		$31K Sell
155
-45
-23% -$9.81K ﹤0.01% 6208
2016
Q3 		$49K Buy
200
+112
+127% +$39.3K ﹤0.01% 5536
2016
Q2 		$51K Sell
88
-6
-6% -$3.52K ﹤0.01% 5507
2016
Q1 		$50K Buy
94
+41
+77% +$21.4K ﹤0.01% 5512
2015
Q4 		$38K Buy
+53
New +$34.8K ﹤0.01% 6084

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

UBS Group's MCRB Position: Q2 2026 in Review

UBS Group reduced its Seres Therapeutics (MCRB) stake by 93% in Q2 2026, selling an estimated $49.8K and leaving 484 shares worth $3.82K. The position accounts for ﹤0.01% of the portfolio, ranked #9142.

UBS Group first reported a position in MCRB in Q4 2015 and has held it in 43 quarters since. The position peaked at $2.75M in Q3 2021. 36 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

  • UBS Group held 484 shares of Seres Therapeutics worth $3.82K as of Q2 2026.
  • UBS Group sold 6,546 Seres Therapeutics shares in Q2 2026, an estimated $49.8K.
  • Seres Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9142 holding.
  • UBS Group first reported a position in Seres Therapeutics in Q4 2015 and has held it in 43 quarters since.
  • UBS Group's Seres Therapeutics position peaked at $2.75M in Q3 2021.
  • 36 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.